BCL2L1 and non-small cell lung carcinoma: Similar to our findings, in NSCLC cell lines with EGFR mutations, Lu et al. discovered an upregulation of Bcl-2 and Bcl-xL as a mechanism to escape cell death via tyrosine kinase inhibitors and sensitized them via BH3 mimetics [22].